SwaminathanPadmanabhan(Padmanabhan)IyerMD

PubMed

• Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma.
  Clark Andersen, Amy Ayers, Michael L Wang, Francisco Vega, Lynne Nguyen, Lorna McNeill, Kehe Zhang, Cici Bauer, Christopher R Flowers, Chijioke Nze, Jason R Westin, Sw...> ;Blood Advances. 2024 Mar 23
• The Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance.
  Mario L Marques-Piubelli, Kirill A Lyapichev, Aakash Fnu, Beatriz Adrada, John Stewart, Kelly K Hunt, Mark W Clemens, Swaminathan Iyer, Yun Wu, Siba El Hussein, Jie Xu...> ;The American Journal of Surgical Pathology. 2024 Mar 4
• Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma.
  Wei, Q., Nwogbo, O., You, M., Medeiros, L., Quesada, A., Hu, S., Li, S., Toruner, G., Loghavi, S., Ok, C., Jain, P., Thakral, B., Kim, D., Iyer, S., Tang, G.> ;Human Pathology. 2024 Feb 1
• Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.
  Stefan K Barta, Iyer, S., Johnston, P.> ;Blood Advances. 2024 Jan 23
• Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system i...
  Fetooh, A., Nair, R., Malpica, L., Wang, M., Lionel, A., Gurumurthi, A., Eldaya, R., Ahmed, S., Iyer, S., Nastoupil, L., Westin, J., Fayad, L., Tummala, S., Flowers, C...> ;Leukemia & Lymphoma. 2024 Jan 22
• Corrigendum to "Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic rel...
  L Jeffrey Medeiros, Mario L Marques-Piubelli, Valentina F I Sangiorgio, Roberto Ruiz-Cordero, Francisco Vega, Andrew L Feldman, Jennifer R Chapman, Mark W Clemens, Kel...> ;Modern Pathology. 2023 Dec 1
• Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
  Max J Gordon, Zhigang Duan, Hui Zhao, Loretta Nastoupil, Samuel Ng, Alexey V Danilov, Swaminathan Iyer, Sharon H Giordano> ;Leukemia & Lymphoma. 2023 Dec 1
• 6 citations
  Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.
  Paolo Strati, Xubin Li, Qing Deng, Mario L Marques-Piubelli, Jared Henderson, Grace Watson, Laurel Deaton, Taylor Cain, Haopeng Yang, Vida Ravanmehr, Luis E Fayad, Swa...> ;Cell Reports. Medicine. 2023 Aug 15
• 2 citations
  Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter ...
  Swaminathan P Iyer, Auris Huen, Weiyun Z Ai, Deepa Jagadeesh, Mary J Lechowicz, Craig Okada, Tatyana A Feldman, Paola Ghione, Juan P Alderuccio, Rebecca Champion, Seo-...> ;Haematologica. 2024 Jan 1
• 6 citations
  A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
  Paolo Strati, Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng, Ryan Sun, Sherry Adkins, Swapna Johncy, Taylor Cain, Raphael E Steiner, Sairah Ahmed, Dai Chihara, Luis E ...> ;Blood Advances. 2023 Nov 14
• 1 citations
  Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma.
  Susan Y Wu, Penny Q Fang, Ethan B Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E Malpica Castillo, Ranjit Nair, Raphael E Steiner, Paolo Strati, Auris O Hu...> ;Advances in Radiation Oncology. 2023 Jun 2
• Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
  Taha Al-Juhaishi, Yingjun Wang, Denái R Milton, Zijun Y Xu-Monette, Elias Jabbour, May Daher, Jin S Im, Qaiser Bashir, Swaminathan P Iyer, David Marin, Amanda L Olson,...> ;Bone Marrow Transplantation. 2023 Sep 1
• 2 citations
  Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
  Christopher N Nguyen, Swaminathan P Iyer, Madeleine Duvic, Prajak J Barde, Ajit Nair, Kasi Viswanath Routhu, Auris O Huen> ;Investigational New Drugs. 2023 Apr 1
• 41 citations
  A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
  Christoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, Viktoria Blumenberg, Maria-Luisa Schubert, Uria Mor, Matthias A Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayas...> ;Nature Medicine. 2023 Apr 1
• Newer insights on how to TEC down T-ALL.
  Swaminathan P Iyer> ;Blood. 2023 Feb 2
• 15 citations
  Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
  Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, ...> ;Journal of Clinical Oncology. 2023 Feb 1
• 3 citations
  From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
  Karen A Nahmod, Beenu Thakral, F N U Aakash, Swaminathan P Iyer, L Jeffrey Medeiros, Andres E Quesada> ;Annals of Diagnostic Pathology. 2023 Feb 1
• 2 citations
  Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavot...
  Leo I Gordon, Reem Karmali, Jason B Kaplan, Rakesh Popat, Howard A Burris 3rd, Silvia Ferrari, Sumit Madan, Manish R Patel, Giuseppe Gritti, Dima El-Sharkawi, F Ian Ch...> ;Oncotarget. 2023 Jan 26
• 11 citations
  rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.
  Lianqun Qiu, Guilin Tang, Shaoying Li, Francisco Vega, Pei Lin, Sa A Wang, Wei Wang, Swaminathan P Iyer, Luis Malpica, Roberto N Miranda, Sergej Konoplev, Zhenya Tang,...> ;Haematologica. 2023 Jun 1
• 5 citations
  Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
  Andrew P Jallouk, Sushanth Gouni, Jason Westin, Lei Feng, Haleigh Mistry, Raphael E Steiner, Jinsu James, Mansoor Noorani, Sandra Horowitz, Nahum Puebla-Osorio, Luis E...> ;Haematologica. 2023 Apr 1
• 1 citations
  Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
  Rishab Prakash, Vivek Subbiah, Swaminathan P Iyer> ;Cancer Journal. 2022 Nov 16
• 8 citations
  Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
  Paolo Strati, Andrew P Jallouk, Ryan Sun, Jaihee Choi, Kaberi Das, Hua-Jay Cherng, Sairah Ahmed, Hun J Lee, Swaminathan P Iyer, Ranjit Nair, Loretta J Nastoupil, Rapha...> ;Leukemia. 2022 Nov 1
• 14 citations
  Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
  Kerry J Savage, Steven M Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Ke...> ;Blood Advances. 2022 Oct 11
• 19 citations
  Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
  Guangchun Han, Qing Deng, Mario L Marques-Piubelli, Enyu Dai, Minghao Dang, Man Chun John Ma, Xubin Li, Haopeng Yang, Jared Henderson, Olga Kudryashova, Mark Meerson, ...> ;Blood Cancer Discovery. 2022 Sep 6
• Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
  Andres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, Abraham S Kanate, Michelle Quinlan, Petra Hoever, Miguel Izquierdo, Jaclyn Davis, Sumit Madan> ;Clinical Pharmacology in Drug Development. 2022 Sep 1
• Join now to see all

Journal Articles

• A unique aptamer-drug conjugate for targeted therapy of multiple myeloma  
  Wen J, Tao W, Hao S, Iyer SP, Zu Y., Leukemia, 8/5/2015
• A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple...  
  Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC, Br J of Haematol, 8/1/2014
• BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD  
  Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer SP, Bradner JE, Bhalla KN, Mol Cancer Ther, 7/1/2014
• Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses  
  Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J..., J Hematol Oncol., 1/23/2014
• Phase I Study of the Investigational Aurora A Kinase Inhibitor MLN8237 (alisertib) in Patients with Relapsed or Refractory Multiple Myeloma, Non-Hodgkin's Lymphoma and...  
  Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Padmanabhan Iyer S, Invest New Drugs, 12/1/2013
• A phase I trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma  
  Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagganath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS, Blood, 11/1/2012
•  
  Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP, Bansal S, J Biol Chem, 9/1/2012
• Results From a Pivotal, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy  
  Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, C..., J Clin Oncol, 2/1/2012
• Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study  
  Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A for the Hx-CD20-406 Study Investigators, Blood, 11/1/2011
• A Cancer Survivorship Study of Perceptions Among Leukemia Patients in the Acute, Extended, and Permanent Survival Phases  
  Pandya DM, Patel S, Ketchum NS, Pollock BH, Padmanabhan S, Clin Lymphoma Myeloma Leuk, 6/1/2011
• Heat shock protein 90 regulates the expression of Wilms' tumor 1 protein in myeloid leukemias  
  Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padman..., Blood, 11/1/2010
• Phase II Trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom’s Macroglobulinemia  
  Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, ..., Am J Hematol, 6/4/2010
• Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors  
  Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ, Target Oncol, 4/1/2009
• Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib  
  Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F, Drug Design, Development and Therapy, 1/1/2009
• Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide, and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed...  
  Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T, Bone Marrow Transplant, 4/1/2008
• High prevalence of early onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy  
  Yao S, McCarthy PL, Dunford LM, Roy DM, Brown K, Paplham P, Syta M, Lamonica D, Smiley S, Battiwalla M, Padmanabhan S, Hahn T, Bone Marrow Transplant, 2/1/2008
• HLA-identical sibling stem cell transplantation in first remission AML  
  Ailawadhi S, Padmanabhan S, Blood, 12/1/2007
• Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature  
  Padmanabhan S, Battiwalla M, Hahn T, Ball D, Paplham P, Brown K, Segal BH, McCarthy P Jr, Almyroudis NG, Transpl Infect Dis, 6/1/2007
• Herpes simplex infections in Solid and Bone marrow transplantations, A Review  
  Varadarajan P and Padmanabhan S, Infectious Disease Practice, 5/1/2007
• Long Term Stability of a Patient-Convenient One mg/mL Suspension of Tacrolimus for Accurate GVHD Prophylaxis Dosing and Maintenance of Stable Therapeutic Levels  
  Elefante, J Muindi, S. Abel, P. Paplham, K. Brown, T. Hahn, S. Padmanabhan, M. Battiwalla, P L. McCarthy Jr, Bone Marrow Transplant, 4/1/2006
• Human Leukocyte Antigen (HLA) DR15 is Associated With Reduced Incidence Of Acute GVHD in HLA-matched Allogeneic Transplants But Does Not Impact Chronic GVHD Incidence  
  Battiwalla M, Hahn T, Radovic M, Roy H, Wahab A, Duman E, Bajwa R, Padmanabhan S, Becker J, Barrett AJ, McCarthy Jr PL, Blood, 1/1/2006
• Simultaneous presentation of acute myeloid leukemia (FAB-M5a) and mantle cell lymphoma: a case report and review of literature  
  Pawarode A, Baer MR, Padmanabhan S, Wallace PR, Barcos M, Sait S, Wetzler M, Battiwalla M, Leuk Lymphoma, 12/1/2005
• Protein Kinase C BetaII Plays an Essential Role in Dendritic Cell Differentiation and autoregulates its own expression  
  Cejas PJ, Carlson LM, Zhang J, Padmanabhan S , Kolonias D, Lindner I, Haley S, Boise LH and Lee KP, J. Biol. Chem, 8/1/2005
• CD8 T cell and Clinical Response to Allogeneic Whole Cell Immunization of patients with Advanced Non Small Cell Lung Carcinoma  
  Raez LE, Cassileth PA, Schlesselman JL, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar KS and Podack ER, Cancer Gene Therapy, 1/1/2003
• Join now to see all

Books/Book Chapters

• Breast Cancer- A Practical Guide 
  Iyer SP et al.Editors: Silva, Orlando E. & Zurrida, Stefano.Elsevier Saunders PublishersEdition 3rd,2005

Abstracts/Posters

• MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Novel CD4+CD8+ Umbilical Cord Blood Regulatory T Cells
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (_65 years) Patients with Mantle Cell Lymphoma (MCL) _ Results from a...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Swami P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Single Injection of Cord Blood Regulatory T Cells Can Delay the Manifestations of Systemic Lupus Erythematosus
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells
  Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Karissa Peth, Laxmi U.M.R. Jakkula, PhD, Melissa Rodrigue..., Molecular Pharmacology, Drug Resistance: Molecular Mechanisms of Drug Resistance and Novel Targets in Acute Myeloid Leukemia, 12/9/2013
• Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD
  Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S, Bhavin Shah, Santhana Devaraj, Ph.D, Swa..., Molecular Pharmacology, Drug Resistance, 12/9/2013
• A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma
  Carol A. Huff, MD, Swaminathan Padmanabhan, MD, Kevin R. Kelly, MD, George Somlo, MD, Luis Camacho, MD, MPH, Jeffrey Zonder, MD, Bruce Fischer, MD, Lixin Lang, Steven ..., Myeloma - Therapy, excluding Transplantation, 12/12/2011
• Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma
  Bertrand Coiffier, MD, Barbara Pro, MD, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Francine M. Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dol..., Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma, 12/12/2011
• The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies
  Patrick Griffin, MD, Steffan T Nawrocki, PhD, Takashi Satou, PhD, Claudia M Espitia, MS, Kevin R. Kelly, MD, Maki Hasegawa, Swaminathan Padmanabhan, MBBS, MD, Angela R..., Acute Myeloid Leukemia - Therapy, excluding Transplantation: Novel Strategies and Preclinical Studies, 12/12/2011
• A Phase I study of BHQ880, a novel osteoblast activating, anti-DKKi human Mab in relapsed and refractory multiple myleloma patients treated with zolendronic acid and a...
  S Padmanabhan, J Beck ,A Stewart ,J Shah ,K Kelly ,K Anderson ,S Bilic ,LM Chiang ,A Dzik-Jurasz ,R Isaacs ,M Li ,P Savage ,M Song ,N Munshi, European Hematology Association, 1/1/2011
• Final Analysis From the International Trial of Single-Agent Ofatumumab in Patients With Fludarabine-Refractory Chronic Lymphocytic Leukemia
  William G. Wierda, Thomas J. Kipps, Jiri Mayer, Tadeusz Robak, Martin J.S. Dyer, Richard Furman, Peter Hillmen, Stephan Stilgenbauer, Andrzej Hellmann, Cathy Williams,..., Therapy, excluding Transplantation: Relapsed/Refractory Disease and Therapeutic Problems, 12/7/2010
• Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) in Patients with Advanced Acute Leukemias
  Ivana Gojo, M.D, Alison Walker, MD, Maureen Cooper, MD, Eric J. Feldman, MD, Swaminathan Padmanabhan, MD, Maria R. Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, D..., Acute Myeloid Leukemia - Therapy, excluding Transplantation, 12/6/2010
• Phase I study of an Investigational Aurora A Kinase Inhibitor MLN8237 in Patients with Advanced Hematologic Malignancies
  Swaminathan Padmanabhan, Thomas C. Shea, Julie M Vose, Craig B. Reeder, Jesus G. Berdeja, Kevin T. McDonagh, André Goy,Kevin Kelly, Xiaofei Zhou, Hua Liu, Howard Fing..., Lymphoma - Chemotherapy, excluding Pre-Clinical Models, 12/5/2010
• A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogen...
  Edgar Castillo MD, Raed Al-Rajabi MD, Devesh Pandya MD, Prakash Varadarajan MD, and Swaminathan Padmanabhan MBBS, MD, Acute Lymphoblastic Leukemia - Therapy, excluding Transplantation, 12/5/2010
• Join now to see all

Lectures

• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Plenary Session-Chronic Lymphocytic Leukemia 
  2/14/2014
• Non-Hodgkin’s Lymphoma- western Database 
  11/22/2013
• Plenary Session- Emerging therapies for Myelofibrosis 
  2/22/2013
• State of the Art Lecture: Treatment Breakthroughs for Relapsed CML 
  9/1/2012
• Should Steroids still be the First Choice for Newly Diagnosed ITP? 
  2/23/2012
• Emerging therapies for TKI refractory/TKI resistant bcr-abl mutations 
  9/2/2011
• Stressing the Importance of Heat Shock Protein90 (HSP90) in Leukemia 
  11/1/2010
• Treatment of MDS in the Era of Novel Agents 
  2/1/2010
• What is new in the treatment of Multiple myeloma 
  10/1/2009
• Opportunities for Clinical Studies in Hematological Malignancies 
  1/1/2009
• Clinical perspectives of flow cytometry in hematological malignancies 
  12/17/2007
• An Overview of Drug Development in Myelodysplastic syndromes 
  11/28/2007
• Acute Leukemia: New Treatments & Promises 
  11/3/2007
• Making Sense of Myelodysplastic Syndromes: From Diagnosis to Treatment 
  10/9/2007
• Evolution in treatment for Multiple Myeloma: Do emerging therapies offer an advantage? 
  9/13/2006
• Advances in Bone Marrow Transplantation: an update for physicians 
  4/24/2006
• Evolving paradigms of managing chronic lymphocytic leukemia-Have we arrived at a cure 
  11/29/2005
• Role of Methyl-Transferase Inhibitors in Hematologic Malignancies 
  11/11/2005
• Current Modalities of management in Chronic Lymphocytic Leukemia 
  10/1/2005
• Clinical Guidelines for Blood & Marrow Transplantation: New Indications for Treatment and Long-Term Assessment-Who are the ideal patients with Lymphoma and Myeloma for... 
  7/1/2005
• Updates on Advances for Treatment of Hematologic Disorders-Review in Chronic Lymphocytic Leukemia 
  1/1/2005
• Join now to see all